IITRI is highly experienced with evaluating the efficacy of potential cancer therapeutics using xenograft models. We have worked extensively with the National Cancer Institute (NCI) to evaluate the efficacy of hundreds of anticancer agents, including many FDA-approved agents.

We work hand-in-hand with our sponsors to design experiments, select the appropriate screening methods and the appropriate xenograft model to evaluate a new drug candidate.

Xenograft Models

Disease Cell Line Mouse Strain
Lung cancer NCI-H522, NCI-H460, A549, NCI-H1975 Nude
Colorectal cancer COLO-205, HT29, HCT116, Caco-2, RKO Nude
Breast cancer MCF-7, T47D, MDA-MB-231 Nude, SCID
Prostate cancer PC-3, DU-145 Nude
Ovarian cancer OVCAR-3, OVCAR-5 Nude, SCID
Renal cancer RXF-393, CakI-1, A498 Nude
Melanoma cancer MDA-MB-435 Nude
Pancreatic cancer PANC-1 Nude
Liver cancer Hep G2 Nude

Additional Efficacy Models

  • Cancer cell lines
  • Mouse mammary gland organ culture
  • Transgenic animal models
  • Chemical carcinogenesis
  • Inflammation-induced carcinogenesis
  • Precancerous legions


  • Tumor growth delay (latency, TGD)
  • Tumor growth inhibition (TGI)
  • IC50
  • Toxicity
  • Survival
  • Combination approaches

The IITRI Advantage

  • A highly experienced team of cancer biology scientists, with more than 250 publications
  • On-site bioanalytical laboratory for prompt analysis of preclinical samples
  • Personalized study design for non-standard and customized studies
  • Technical advisory and support regarding interpretation of study results

Related Services